Evaluating Antiplatelet and Anticoagulation Therapy in Hereditary Hemorrhagic Telangiectasia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the tolerance of anticoagulant and/or antiplatelet therapy in patients with Hereditary Hemorrhagic Telangiectasia (HHT) by comparing a new treatment exposure period to a reference non-exposure period. Participants will be monitored over two years, with evaluations including biological monitoring of ferritin and hemoglobin levels, as well as questionnaires assessing epistaxis severity and quality of life. The study seeks to identify which therapies are best tolerated in this patient population, where current treatment guidelines are lacking.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with Rendu-Osler disease with an indication of antiplatelet and/or anticoagulant introduced for less than 3 months (inclusion period within 3 months of exposure)
* Age \> 18 years old
* Patient able to understand and agree to participate in the study
* Affiliation to a social security system

Exclusion Criteria:

* Patient with an indication of antiplatelet and/or anticoagulant but for whom treatment has not been introduced or introduced for more than 3 months
* Refusal to participate
* Pregnant woman or who are breast feeding
* Patients under maintenance of justice, wardship or legal guardianship

Where it's running

• CHU d'Angers
  Angers, France Recruiting
• CHU de Bordeaux
  Bordeaux, France Recruiting
• CHU de Caen Normandie
  Caen, France Recruiting
• CHU clermont-ferrand
  Clermont-Ferrand, France Recruiting
• CHU de Dijon
  Dijon, France Recruiting
• Hospices Civiles de Lyon
  Lyon, France Recruiting

Study contacts

• Principal investigator: Vincent GROBOST — University Hospital, Clermont-Ferrand
• Study coordinator: Lise Laclautre
• Email: promo_interne_drci@chu-clermontferrand.fr
• Phone: 334.73.754.963

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Body donation in HHT

  This study tests whether donated human tissue with and without vascular malformations from people with hereditary hemorrhagic telangiectasia can be analyzed to better understand the disease.

  Recruiting University Hospital, Essen · Essen, North Rhine-Westphalia · NCT07826845

• Engasertib for moderate to severe HHT: see if daily 40 mg helps with nosebleeds

  This trial tests whether taking engasertib once daily for 28 weeks reduces nosebleed frequency in adults with hereditary hemorrhagic telangiectasia compared with placebo.

  Recruiting at 4 sites Phase 3 Vaderis Therapeutics AG · Chicago, Illinois and 3 other locations · NCT07743671

• DIAG723 in Adults With HHT

  A first-in-human study tests DIAG723 versus placebo in adults with hereditary hemorrhagic telangiectasia to see if it is safe and possibly helpful.

  Recruiting at 3 sites Phase 1/2 Diagonal Therapeutics, Inc. · Camperdown, New South Wales and 10 other locations · NCT07623525

• Registry for patients with Hereditary Hemorrhagic Telangiectasia

  This study is collecting information from people with Hereditary Hemorrhagic Telangiectasia to better understand the condition and help improve treatments in the future.

  Recruiting at 16 sites Cure HHT · Birmingham, Alabama and 15 other locations · NCT06259292

• Examining the role of hypoxia in hereditary hemorrhagic telangiectasia

  This study looks at how low oxygen levels might affect people with hereditary hemorrhagic telangiectasia (HHT) and how it could change the way the disease develops.

  Recruiting University Hospital, Essen · Essen, North Rhine-Westphalia · NCT04469517

• Using nintedanib to treat nosebleeds in patients with hereditary hemorrhagic telangiectasia

  This study is testing if the medication nintedanib can help reduce the number and severity of nosebleeds in people with hereditary hemorrhagic telangiectasia.

  Recruiting at 2 sites Phase 2 Centre Hospitalier Universitaire Vaudois · Bron and 2 other locations · NCT04976036

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.